Spots Global Cancer Trial Database for cutaneous melanoma
Every month we try and update this database with for cutaneous melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors | NCT05571839 | Cutaneous Melan... Non-small Cell ... Colorectal Neop... Pancreatic Neop... Mesothelioma | SGN-BB228 | 18 Years - | Seagen Inc. | |
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | NCT05549297 | Advanced Melano... | Tebentafusp Tebentafusp wit... Investigators C... | 18 Years - | Immunocore Ltd | |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | NCT06346067 | Advanced or Met... | Naporafenib Dacarbazine Temozolomide Trametinib | 18 Years - 99 Years | Erasca, Inc. | |
| PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma | NCT02288897 | Cutaneous Melan... | PV-10 (10% rose... Dacarbazine, te... | 18 Years - | Provectus Pharmaceuticals | |
| Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma | NCT04702854 | Cutaneous Melan... | Ultrasound Biom... | 18 Years - | Centre Hospitalier Universitaire de Nice | |
| A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | NCT04551352 | Cutaneous Melan... Uveal Melanoma Mucosal Melanom... | RO7293583 Tocilizumab Obinutuzumab Adalimumab | 18 Years - | Hoffmann-La Roche | |
| Neoadjuvant Atezolizumab in Cutaneous Melanoma | NCT04020809 | Cutaneous Melan... | Atezolizumab | 18 Years - | The Methodist Hospital Research Institute | |
| Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib | NCT03235245 | Unresectable St... Stage IV Melano... | Nivolumab + Ipi... Encorafenib + B... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma | NCT06319196 | Cutaneous Melan... Melanoma Stage ... Mucosal Melanom... | Opdualag Nivolumab | 18 Years - | University Health Network, Toronto | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma | NCT00273910 | High-Risk Melan... | gp100:209-217 (... Montanide ISA-5... Imiquimod | 7 Years - | National Institutes of Health Clinical Center (CC) | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi | NCT01444560 | Cutaneous Melan... Nevi | 1 Year - | Ruhr University of Bochum | ||
| Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma | NCT02968680 | Cutaneous Melan... Melanoma | Sentinel Lymph ... Ultrasonography Sonazoid | 19 Years - | University of Southern California | |
| Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors | NCT05283330 | Cervical Cancer Prostate Cancer... Breast Cancer Colon Cancer NSCLC Cutaneous Melan... | ²¹²Pb-DOTAM-GRP... | 18 Years - | Orano Med LLC | |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | NCT06346067 | Advanced or Met... | Naporafenib Dacarbazine Temozolomide Trametinib | 18 Years - 99 Years | Erasca, Inc. | |
| Exercise to Boost Response to Checkpoint Blockade Immunotherapy | NCT05358938 | Cutaneous Melan... Cutaneous Squam... Merkel Cell Car... | Exercise Checkpoint Bloc... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Advanced Non-invasive Diagnostics for Early Cutaneous Tumor Diagnosis, Clinical-therapeutic and Economic Management | NCT04789421 | Cutaneous Melan... | Clinical, dermo... Clinical, dermo... | 18 Years - | Azienda Ospedaliero-Universitaria di Modena | |
| A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | NCT05970497 | Cancer Melanoma Stage ... Melanoma Stage ... Cutaneous Melan... Osteosarcoma Carcinoma, Squa... Carcinoma, Basa... | KB707 | 18 Years - | Krystal Biotech, Inc. | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | NCT04254107 | Non-small Cell ... Gastric Carcino... Gastroesophagea... Classical Hodgk... Diffuse Large B... Peripheral T-ce... Cutaneous Melan... Head and Neck S... Bladder Cancer Ovarian Cancer Triple Negative... Cervical Cancer | SEA-TGT sasanlimab brentuximab ved... | 18 Years - | Seagen Inc. | |
| Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer | NCT00328861 | Metastatic Mela... Metastatic Kidn... | Natural Killer ... IL-2 Cyclophosphamid... Fludarabine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Validation of Ferromagnetic Tracer in Melanoma Sentinel Node | NCT03449615 | Melanoma Stage Sentinel Lymph ... | 18 Years - | Sociedad Española de Oncología Quirúrgica | ||
| A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors | NCT02988960 | Advanced Solid ... | ABBV-927 ABBV-927 ABBV-181 | 18 Years - | AbbVie | |
| The MELAcare Study: A New Method for Surveillance of Melanoma Patients | NCT05253872 | Cutaneous Melan... | The MelaCare in... | 18 Years - | Herlev and Gentofte Hospital | |
| EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers | NCT06223659 | Cutaneous Melan... Merkel Cell Car... Skin Squamous C... | Eutectic Mixtur... Placebo Adminis... Questionnaire A... | 18 Years - 99 Years | Ohio State University Comprehensive Cancer Center | |
| 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy | NCT03278665 | Malignant Melan... | 4SC-202 in comb... | 18 Years - | 4SC AG | |
| Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma | NCT00679289 | Metastatic Mela... Cutaneous Melan... | HDI KW2871 KW2871 KW2871 | 18 Years - | Ludwig Institute for Cancer Research | |
| Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma | NCT02447939 | Melanoma | Dabrafenib Trametinib | 18 Years - | GlaxoSmithKline | |
| Neoadjuvant and Adjuvant Checkpoint Blockade | NCT02519322 | Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ... | Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con... | 18 Years - | M.D. Anderson Cancer Center | |
| Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma | NCT00273910 | High-Risk Melan... | gp100:209-217 (... Montanide ISA-5... Imiquimod | 7 Years - | National Institutes of Health Clinical Center (CC) | |
| Minimal SN Tumor Burden | NCT01942603 | Cutaneous Melan... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | ||
| A Study of SGN-CD228A in Advanced Solid Tumors | NCT04042480 | Cutaneous Melan... Pleural Mesothe... HER2 Negative B... Non-small Cell ... Colorectal Canc... Pancreatic Duct... | SGN-CD228A | 18 Years - | Seagen Inc. | |
| The MELAcare Study: A New Method for Surveillance of Melanoma Patients | NCT05253872 | Cutaneous Melan... | The MelaCare in... | 18 Years - | Herlev and Gentofte Hospital | |
| Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma | NCT04778449 | Cutaneous Melan... | Medical Chart R... Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Neoadjuvant Combination Immunotherapy for Stage III Melanoma | NCT03842943 | Cutaneous Melan... | Pembrolizumab Talimogene Lahe... | 18 Years - | University of Louisville | |
| Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma | NCT01763164 | Metastatic or U... | MEK162 Dacarbazine | 18 Years - | Pfizer | |
| Minimal SN Tumor Burden | NCT01942603 | Cutaneous Melan... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | ||
| Location of Lower Limb Cutaneous Melanomas as a Prognostic Factor. | NCT04625491 | Cutaneous Melan... Anatomical Path... | Observational | - | Hospital Universitario Virgen de la Arrixaca | |
| Confirmatory Trial in the Evaluation of Ca Electroporation for the Treatment of Cutaneous Metastases | NCT03628417 | Cutaneous Melan... | Calcium Electro... Bleomycin based... | 18 Years - 100 Years | Szeged University | |
| IMCgp100-401 Rollover Study | NCT02889861 | Malignant Melan... | IMCgp100 | 18 Years - | Immunocore Ltd | |
| Neoadjuvant and Adjuvant Checkpoint Blockade | NCT02519322 | Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ... | Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con... | 18 Years - | M.D. Anderson Cancer Center | |
| TH1902 in Patients With Advanced Solid Tumors | NCT04706962 | Solid Tumor TNBC - Triple-N... Hormone Recepto... Epithelial Ovar... Endometrial Can... Cutaneous Melan... Thyroid Cancer Small-cell Lung... Prostate Cancer SORT1+ Cancers | TH1902 | 18 Years - | Theratechnologies | |
| Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | NCT03633110 | Cutaneous Melan... Non-small Cell ... Squamous Cell C... Urothelial Carc... Renal Cell Carc... | GEN-009 Adjuvan... Nivolumab Pembrolizumab | 18 Years - | Genocea Biosciences, Inc. | |
| Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma | NCT01693068 | N-Ras Mutated L... | Pimasertib Dacarbazine | 18 Years - | EMD Serono | |
| Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | NCT05482074 | Recurrent Metas... Cutaneous Melan... Mucosal Melanom... Uveal Melanoma | Olaparib | 18 Years - | Dana-Farber Cancer Institute | |
| Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma | NCT01827111 | Melanoma | ABI-007 Ipilimumab Phone Call | 12 Years - 70 Years | M.D. Anderson Cancer Center | |
| Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma | NCT02447939 | Melanoma | Dabrafenib Trametinib | 18 Years - | GlaxoSmithKline | |
| Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma | NCT06319196 | Cutaneous Melan... Melanoma Stage ... Mucosal Melanom... | Opdualag Nivolumab | 18 Years - | University Health Network, Toronto | |
| Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver | NCT01728051 | Metastatic Live... Ocular Melanoma Cutaneous Melan... | Melphalan Percutaneous He... | 18 Years - | Delcath Systems Inc. | |
| Exercise to Boost Response to Checkpoint Blockade Immunotherapy | NCT05358938 | Cutaneous Melan... Cutaneous Squam... Merkel Cell Car... | Exercise Checkpoint Bloc... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| RTX-224 Monotherapy in Patients With Solid Tumors | NCT05219578 | Non Small Cell ... Cutaneous Melan... Head and Neck S... Urothelial Carc... TNBC - Triple-N... | RTX-224 | 18 Years - | Rubius Therapeutics | |
| Enhancing Skin Cancer Early Detection and Treatment in Primary Care | NCT05675709 | Cutaneous Melan... | Training and Ed... | 18 Years - | OHSU Knight Cancer Institute | |
| Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma | NCT04778449 | Cutaneous Melan... | Medical Chart R... Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Neoadjuvant Combination Immunotherapy for Stage III Melanoma | NCT03842943 | Cutaneous Melan... | Pembrolizumab Talimogene Lahe... | 18 Years - | University of Louisville | |
| Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | NCT05520099 | Colorectal Canc... Head and Neck S... Non Small Cell ... Cutaneous Melan... Endometrial Can... Urothelial Carc... Clear Cell Rena... | Core Needle or ... | 18 Years - | Elephas | |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | NCT05059444 | Bladder Carcino... Ureter Carcinom... Renal Pelvis Ca... Non-small Cell ... Invasive Breast... Cutaneous Melan... Esophageal Carc... Gastroesophagea... Gastric Adenoca... Pancreatic Aden... Squamous Cell C... Epithelial Ovar... Fallopian Tube ... Endometrial Car... Renal Cell Carc... | Guardant Reveal | 18 Years - | Guardant Health, Inc. | |
| A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery | NCT03843593 | Cutaneous Melan... | Demographics Qu... Adjuvant Treatm... Functional Asse... Functional Asse... Decisional Regr... Clinician Prefe... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Neoadjuvant and Adjuvant Checkpoint Blockade | NCT02519322 | Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ... | Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | NCT03947385 | Metastatic Uvea... Cutaneous Melan... Colorectal Canc... Other Solid Tum... | IDE196 Binimetinib Crizotinib | 18 Years - | IDEAYA Biosciences | |
| Exercise to Boost Response to Checkpoint Blockade Immunotherapy | NCT06008977 | Cutaneous Melan... Cutaneous Squam... Merkel Cell Car... | Exercise Test | 18 Years - | AdventHealth Translational Research Institute | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors | NCT05576077 | Breast Cancer Colorectal Canc... Uveal Melanoma Cutaneous Melan... Non-Small Cell ... Head and Neck S... | TBio-4101 Pembrolizumab | 18 Years - 70 Years | Turnstone Biologics, Corp. | |
| Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver | NCT01728051 | Metastatic Live... Ocular Melanoma Cutaneous Melan... | Melphalan Percutaneous He... | 18 Years - | Delcath Systems Inc. | |
| Study of RP1 Monotherapy and RP1 in Combination With Nivolumab | NCT03767348 | Cancer Melanoma (Skin) Mismatch Repair... Microsatellite ... Non-melanoma Sk... Cutaneous Melan... NSCLC | RP1 nivolumab | 18 Years - | Replimune Inc. | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma | NCT02447939 | Melanoma | Dabrafenib Trametinib | 18 Years - | GlaxoSmithKline | |
| A Study of GV20-0251 in Patients With Solid Tumor Malignancies | NCT05669430 | Solid Tumor, Ad... Refractory Canc... Bladder Urothel... Cholangiocarcin... Adenocarcinoma ... Endometrial Car... Head and Neck C... Cutaneous Melan... Non-small Cell ... Adenocarcinoma ... | GV20-0251 GV20-0251 | 18 Years - | GV20 Therapeutics | |
| Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma | NCT00679289 | Metastatic Mela... Cutaneous Melan... | HDI KW2871 KW2871 KW2871 | 18 Years - | Ludwig Institute for Cancer Research | |
| A Study of SGN-CD228A in Advanced Solid Tumors | NCT04042480 | Cutaneous Melan... Pleural Mesothe... HER2 Negative B... Non-small Cell ... Colorectal Canc... Pancreatic Duct... | SGN-CD228A | 18 Years - | Seagen Inc. | |
| Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer | NCT04121676 | Advanced Cancer | AGEN2373 Botensilimab | 18 Years - | Agenus Inc. | |
| GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors | NCT03693612 | Neoplasms | feladilimab Tremelimumab Docetaxel Paclitaxel Cetuximab | 18 Years - | GlaxoSmithKline | |
| TH1902 in Patients With Advanced Solid Tumors | NCT04706962 | Solid Tumor TNBC - Triple-N... Hormone Recepto... Epithelial Ovar... Endometrial Can... Cutaneous Melan... Thyroid Cancer Small-cell Lung... Prostate Cancer SORT1+ Cancers | TH1902 | 18 Years - | Theratechnologies | |
| 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results | NCT02355574 | Cutaneous Melan... | 16 Years - | Castle Biosciences Incorporated | ||
| Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | NCT05628883 | Metastatic Mela... Unresectable Me... Acral Melanoma Mucosal Melanom... Cutaneous Melan... Ocular Melanoma Uveal Melanoma Iris Melanoma Conjunctival Me... Non-Cutaneous M... | TBio-4101 Cyclophosphamid... Fludarabine Interleukin-2 | 18 Years - 75 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers | NCT06223659 | Cutaneous Melan... Merkel Cell Car... Skin Squamous C... | Eutectic Mixtur... Placebo Adminis... Questionnaire A... | 18 Years - 99 Years | Ohio State University Comprehensive Cancer Center | |
| Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer | NCT00328861 | Metastatic Mela... Metastatic Kidn... | Natural Killer ... IL-2 Cyclophosphamid... Fludarabine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Exercise to Boost Response to Checkpoint Blockade Immunotherapy | NCT05358938 | Cutaneous Melan... Cutaneous Squam... Merkel Cell Car... | Exercise Checkpoint Bloc... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma | NCT02968680 | Cutaneous Melan... Melanoma | Sentinel Lymph ... Ultrasonography Sonazoid | 19 Years - | University of Southern California |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
